BIO-B
Bio-Rad Laboratories IncNYSE
Healthcare • Medical Devices
$379.50+4.22%
Close Oct 27, 2026
- Market cap
- $10.15B
- 1 month
- —
- 3 months
- —
- 1 year
- —
- 52-week range
- $255.54$379.50
- Dividend
- No dividends on record
- Short interest
- 1 sharessettled Sep 30, 2026 · -50.0% since Aug 14, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $2.59B
- Net income
- $222.4M
- Free cash flow
- $353.1M
- Book value
- $7.17B
- Total debt
- $1.2B
- P/E
- 45.6×
- Price / sales
- 3.9×
- Price / book
- 1.4×
- FCF yield
- +3.5%
- Net margin
- +8.6%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.
Read more
The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- Website
- bio-rad.com
- Headquarters
- Hercules, CA, United States
- Employees
- 7,450
- Listed
- Sep 21, 1999
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 22, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 4, 2026 | $651.0M | -0.1% | 53.1% | $72.6M | $371.4M |
| Mar 2026filed Apr 30, 2026 | $592.1M | +1.1% | 52.3% | $34.1M | -$527.1M |
| Dec 2025filed Feb 13, 2026 | $693.2M | +3.9% | 49.8% | $61.9M | $720.0M |
| Sep 2025filed Oct 29, 2025 | $653.0M | +0.5% | 52.6% | $66.4M | -$341.9M |
| Jun 2025filed Jul 31, 2025 | $651.6M | +2.1% | 53.0% | $77.1M | $317.8M |
| Mar 2025filed May 1, 2025 | $585.4M | -4.2% | 52.3% | $23.7M | $64.0M |
| Dec 2024filed Feb 14, 2025 | $667.5M | -2.0% | 51.2% | $58.3M | -$715.8M |
| Sep 2024filed Oct 31, 2024 | $649.7M | +2.8% | 54.8% | $64.5M | $653.2M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 13, 2026 | $2.6B | +0.7% | 52.0% | $270.5M | $759.9M |
| Dec 2024filed Feb 14, 2025 | $2.6B | -3.9% | 53.7% | $269.0M | -$1.8B |
| Dec 2023filed Feb 16, 2024 | $2.7B | -4.7% | 53.4% | $337.8M | -$637.3M |
| Dec 2022filed Feb 17, 2023 | $2.8B | -4.1% | 55.9% | $482.6M | -$3.6B |
| Dec 2021filed Feb 11, 2022 | $2.9B | +14.8% | 56.1% | $500.3M | $4.3B |
| Dec 2020filed Feb 16, 2021 | $2.5B | +10.1% | 56.5% | $421.3M | $3.8B |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched BIO-B. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Sep 30, 2026
1 shares short
-1 shares (-50%) vs Aug 14, 2026
Share of float unavailable. Published Oct 9, 2026.
Settlement Aug 14, 2026
2 shares short
0 shares (0%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
2 shares short
-29 shares (-93.5%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Settlement Jul 15, 2026
31 shares short
-189 shares (-85.9%) vs Jun 30, 2026
Share of float unavailable. Published Jul 24, 2026.
Settlement Jun 30, 2026
220 shares short
+219 shares (+21,900%) vs Jun 15, 2026
Share of float unavailable. Published Jul 10, 2026.
Settlement Jun 15, 2026
1 shares short
-90 shares (-98.9%) vs May 29, 2026
Share of float unavailable. Published Jun 25, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind BIO-B’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
2 for 1 · forward split
Effective Mar 8, 2002
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
3 for 2 · forward split
Effective Jun 3, 1996
Each 2 pre-split shares become 3 post-split shares.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if BIO-B is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
1 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Nov 4, 2026
Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
5 filers reported a long position in BIO-B for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 5 hold
100%
of the 1.8K shares 13-F filers reported
Moves vs Q1 2026
0 added1 trimmed
4 unchanged
Net shares held
-11%
across the 5 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FLOW TRADERS U.S. LLC | $229K · 760 shares | 760 | -22.8% |
| 2 | MORGAN STANLEY | $214.3K · 712 shares | 712 | Unchanged |
| 3 | WELLS FARGO & COMPANY/MN | $50.4K · 170 shares | 170 | Unchanged |
| 4 | WHITTIER TRUST CO | $47.3K · 160 shares | 160 | Unchanged |
| 5 | UBS Group AG | $3.9K · 13 shares | 13 | Unchanged |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inGet the Full Analysis for BIO-B
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.